<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">22773551</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>06</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>01</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-3288</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>62</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Gut</Title>
<ISOAbbreviation>Gut</ISOAbbreviation>
</Journal>
<ArticleTitle>Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).</ArticleTitle>
<Pagination>
<MedlinePgn>751-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/gutjnl-2012-302759</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was compared with a reverse experimental sequence of capecitabine/erlotinib followed by gemcitabine.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">281 patients with PC were randomly assigned to 1st-line treatment with either gemcitabine plus erlotinib or capecitabine plus erlotinib. In case of treatment failure (eg, disease progression or toxicity), patients were allocated to 2nd-line treatment with the comparator cytostatic drug without erlotinib. The primary study endpoint was time to treatment failure (TTF) after 1st- and 2nd-line therapy (TTF2; non-inferiority design). KRAS exon 2 mutations were analysed in archival tumour tissue from 173 of the randomised patients.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 274 eligible patients, 43 had locally advanced and 231 had metastatic disease; 140 (51%) received 2nd-line chemotherapy. Median TTF2 was estimated with 4.2 months in both arms; median overall survival was 6.2 months with gemcitabine/erlotinib followed by capecitabine and 6.9 months with capecitabine/erlotinib followed by gemcitabine, respectively (HR 1.02, p=0.90). TTF for 1st-line therapy (TTF1) was significantly prolonged with gemcitabine/erlotinib compared to capecitabine/erlotinib (3.2 vs 2.2 months; HR 0.69, p=0.0034). Skin rash was associated with both TTF2 (rash grade 0/1/2-4:2.9/4.3/6.7 months, p&lt;0.0001) and survival (3.4/7.0/9.6 months, p&lt;0.0001). Each arm showed a safe and manageable toxicity profile during 1st- and 2nd-line therapy. A KRAS wild-type status (52/173 patients, 30%) was associated with an improved overall survival (HR 1.68, p=0.005).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Both treatment strategies are feasible and demonstrated comparable efficacy; KRAS may serve as biomarker in patients with advanced PC treated with erlotinib.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Heinemann</LastName>
<ForeName>Volker</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians University of Munich, Marchioninistr. 15, D-81377 Munich, Germany. volker.heinemann@med.uni-muenchen.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vehling-Kaiser</LastName>
<ForeName>Ursula</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Waldschmidt</LastName>
<ForeName>Dirk</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kettner</LastName>
<ForeName>Erika</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Märten</LastName>
<ForeName>Angela</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Winkelmann</LastName>
<ForeName>Cornelia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kojouharoff</LastName>
<ForeName>Georgi</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gauler</LastName>
<ForeName>Thomas C</ForeName>
<Initials>TC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>von Weikersthal</LastName>
<ForeName>Ludwig Fischer</ForeName>
<Initials>LF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clemens</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geissler</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Greten</LastName>
<ForeName>Tim F</ForeName>
<Initials>TF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hegewisch-Becker</LastName>
<ForeName>Susanna</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rubanov</LastName>
<ForeName>Oleg</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baake</LastName>
<ForeName>Gerold</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Höhler</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ko</LastName>
<ForeName>Yon D</ForeName>
<Initials>YD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neugebauer</LastName>
<ForeName>Sascha</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boeck</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00440167</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>Z99 CA999999</GrantID>
<Acronym>NULL</Acronym>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Gut</MedlineTA>
<NlmUniqueID>2985108R</NlmUniqueID>
<ISSNLinking>0017-5749</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6804DJ8Z9U</RegistryNumber>
<NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DA87705X9K</RegistryNumber>
<NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Gut. 2013 May;62(5):660-1</RefSource>
<PMID Version="1">22952212</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000465">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069287">Capecitabine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069347">Erlotinib Hydrochloride</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2012</Year>
<Month>7</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2012</Year>
<Month>7</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>6</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22773551</ArticleId>
<ArticleId IdType="pii">gutjnl-2012-302759</ArticleId>
<ArticleId IdType="doi">10.1136/gutjnl-2012-302759</ArticleId>
<ArticleId IdType="pmc">PMC6309814</ArticleId>
<ArticleId IdType="mid">NIHMS999939</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>